Psoriatic arthritis (PsA) is a serious and potentially disabling condition that affects about 30% of patients with psoriasis. The joint involvement of PsA often occurs about 10 years after the appearance of skin disease. In addition to the physical and functional impairments from joint destruction, PsA negatively impacts relationships, activities of daily living, work productivity, and overall quality of life (QoL).  Unfortunately, individuals with PsA are often undiagnosed or misdiagnosed. Dermatologists clearly have an important role in detecting early signs of PsA, and the overlapping treatment needs of patients often require collaborative care between dermatologists and rheumatologists.

This Psoriatic Arthritis Hub is dedicated to providing educational activities, resources, and tools to improve the care of patients with PsA.

Practicing Precision Medicine in Psoriatic Arthritis: Strategies and Digital Health Tools for Managing a Chronic Disease

Several agents have been FDA-approved for the treatment of moderate-to-severe PsA since 2008, and there are still more currently under investigation. In this CME Outfitters Live and On Demand expert faculty will highlight the molecular targets of currently available and emerging biologic treatments for managing PsA, discuss individualized treatment plans, and provide updates on the latest clinical trials focused on the impact of long-term treatment, improving pain, and quality of life.

Watch Now!

The Importance of Treating What Matters to the Patient – Impact of Psoriatic Arthritis Therapies on Patient-Reported Outcomes

In this CME Outfitters CME Snack, expert faculty focus on treat-to-target approaches and digital health tools. Treat-to-target approaches are important for proper treatment as without having targets as ways of measuring how a patient is doing, clinicians have no way of improving on care over time. Digital health tools help both the clinician and the patient by providing both treatment guidelines and the ability to monitor disease progression and medication adherence.

Watch Now!

Personalizing the Care of Patients with Psoriatic Arthritis – Factors Influencing Treatment Selection

Clinicians should be choosing agents based on what the phenotype of disease is, but with consideration to comorbidities. In this CME Outfitters CME Snack, expert faculty discuss and safety of agents used in treating PsA, taking patients’ comorbidities into account.

Watch Now!

Targeted Pathways in Psoriasis and Psoriatic Arthritis – Implications for Improved Patient Outcomes

Join CME Outfitters and our expert faculty in this CME Snack for a discussion about PsA treatment strategies and best implementation practices for current and emerging biologic treatment options with a focus on molecular targets.

Watch Now!

 

SMART Goals for Psoriatic Arthritis

Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:351-360. (PDF)

 

Zhang A, Kurtzman DJB, Perez-Chada LM, Merola JF. Psoriatic arthritis and the dermatologist: an approach to screening and clinical evaluation. Clin Dermatol.2018;36:551-560. (LINK)

 

Elalouf O, Chandran V. Novel therapeutics in psoriatic arthritis: what is in the pipeline? Curr Rheumatol Rep.2018;20:36. (LINK)

 

Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open.2018;4:e000656. (PDF)

 

Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol.2016;12:743-750. (PDF)

 

Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol.2016;68:1060-1071. (PDF)

 

Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis.2016;75:499-510. (PDF)